Tacabrutideg in Moderate and Severe Hepatic Impairment

Phase 1, open-label trial of tacabrutideg in cancer (3 arms), sponsored by BeOne Medicines. Primary endpoints: Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration, Area under the plasma concentration-time curve from time 0 extrapolated to infinity and 6 more. Planned start Dec 2026; status: not yet recruiting.